The De-Rating Plus the Proof We Wanted: ZYN Offtake Accelerates to +39%, Margins Hit a Four-Year High, Dividend Raised 8.9% — Upgrading to Outperform

Results vs. Consensus

Q3 2025 Scorecard

Year-Over-Year Comparisons

Quality of Beat/Miss

Revenue: Reported net revenue beat at $10.8B, but organic growth of +5.9% (roughly +7.3% excluding the Indonesia technical impact) sat at the low end of the 6–8% frame. The drag was not demand: it was the ~$100M ZYN relaunch promotion, effectively all of which was booked as a reduction to Americas net revenue in the quarter. Adjust for that self-inflicted, one-off item and the underlying top line ran solidly inside the algorithm. This is a "we chose to spend it" revenue print, not a "we couldn't sell it" one.

Margins: The standout. Group gross margin of 67.9% (+170bp) is the highest since 2021, smoke-free gross margin reached 70%, and adjusted OI margin of 43.1% is a four-year high. The mechanics are exactly the thesis: smoke-free mix (70% gross margin) plus IQOS scale and cost efficiency drove the gross-margin expansion, partly reinvested below the line in the U.S. buildout. That reinvestment is why organic OI-margin expansion was a more modest +60bp, but the gross-margin engine underneath is running at record efficiency.

EPS: Adjusted EPS of $2.24 grew 17.3% and beat consensus by 7%. The composition is more favorable than Q2's: a $0.08 currency tailwind (this time including a favorable transactional impact, the reverse of Q2's Swiss-franc drag) plus a below-the-line assist from a slightly better tax rate and favorable interest costs. Management was explicit that the double-digit EPS growth is fundamentally OI-driven, with tax "the cherry on the cake." A cleaner, higher-quality EPS beat than the prior quarter.

Segment Performance

Category Mix — Q3 2025

ZYN & U.S. — The Thesis Question, Answered

The U.S. is now ~7% of net revenue and ~9% of adjusted OI year-to-date, and it is the fastest-growing piece of PMI. ZYN U.S. offtake accelerated to +39% (Nielsen), the fastest in five quarters, against a category growing over 40%, with ZYN holding more than 60% volume share and two-thirds of value. The September figure spiked to +58% on the one-off "free can" relaunch promotion; excluding that, underlying offtake still ran 30%+, and the first two weeks of October held near 30%. U.S. can shipments grew +37% to 205 million, ahead of expectation. The trade-off was margin: the roughly $100M relaunch investment plus a normalization of promotional intensity (from an abnormally low ~20%-on-promo in H1 toward a more competitive, though still premium, level) compressed reported Americas economics.

"During a year of limitation in availability for ZYN, we've been flying at a level of profitability that was abnormal, because the level of promotion was very low... now that we are back to full availability, we want to capture our fair share of the growth. ZYN remains and will remain a premium brand." — Emmanuel Babeau, CFO

Assessment: This is the single most important disclosure of the quarter for our rating. At initiation we flagged the ZYN shipment-versus-offtake gap as the swing factor and made resolution of it an explicit upgrade trigger. Offtake at +39% (30%+ underlying) settles it: the franchise is accelerating, not cracking. The margin normalization is real and permanent, but it takes ZYN from an abnormally-high H1 margin back to a still-best-in-class level, which is a healthy trade for durable category leadership in what management believes can become one of the largest nicotine categories in the U.S.

IQOS & Heated Tobacco — The Soft Spot, In Context

IQOS HTU adjusted IMS grew +9.0%, a step down from Q2's +11.4% and below the double-digit bar, but against a demanding ~15% prior-year comparison and with a Q4 acceleration expected (September IMS was already back above 10%). HTU shipments grew +15.5% to 41 billion units, running ahead of IMS on a ~1 billion-unit timing benefit that reverses in Q4 (a ~2 billion-unit shipment reduction is planned as shipments realign to, and possibly below, IMS for the year). Europe delivered a record 15 billion units of adjusted IMS (+7.3%, share +1.2pp to 10.7%, led by Italy), and Japan held HTU share at 31.7% (+1.8pp) with adjusted IMS +6.0%.

"We are north of 75%, and we have been there for the last five, six years, which is quite incredible, because when you have a new segment innovation, normally the leader loses a bit of share... Japan is making no exception. We are very, very stable in terms of share of the category." — Emmanuel Babeau, CFO (on IQOS's Japan category share amid intensifying competition)

Assessment: The IMS deceleration is the one genuine watch item, but it is comp-driven and management reaffirmed the 10–12% full-year IMS target with a Q4 acceleration. The more important signal is competitive: two heavily promoted heat-not-burn launches in Japan failed to dent IQOS's ~75%+ category share, which has held for half a decade. Management framed rising competition as category-expanding and therefore net-positive for the leader, a view we share given the share stability. IQOS is a soft +9% this quarter, not a broken franchise.

VEEV / E-Vapor — Scaling Into Profitability

VEEV shipments grew +91% in Q3 and have more than doubled year-to-date, with the brand now #1 in closed pods in eight markets. An improved pods-to-kit ratio (driven by repeat purchase) is delivering operating leverage, and management reiterated that VEEV is on a path toward IQOS-like percentage gross margins as loyalty builds. VEEV is increasingly sourcing from non-IQOS legal-age nicotine users, which is the strategic point: it widens the funnel rather than cannibalizing the flagship.

Assessment: Still the smallest leg, but the completion of a genuinely three-category smoke-free portfolio strengthens the platform argument. The margin trajectory is the thing to track; the volume is already there.

Combustibles — Resilience, With Even Stronger Pricing

Combustible net revenue grew +4.3% (+1.0% organic) with gross profit up +7.7% (+4.8% organic), on pricing of +8.3% (better than expected, with contributions from Indonesia, Australia, Turkey and Germany). Marlboro reached a post-spin category-share high of 10.9%. Cigarette volume declined 3.2%, at the favorable end of the -3 to -4% H2 guide, helped by better-than-expected Turkey and Egypt dynamics. Management now sees full-year pricing "a little above +7%."

Assessment: Combustibles, still over 50% of the group, did exactly its job: fund the transition. Pricing of +8.3% comfortably out-earned the volume decline, and the gross-profit growth is the cash engine behind the dividend and the U.S. reinvestment. No cracks here.

Key Operating KPIs

Key Topics & Management Commentary

Overall Management Tone: Confident and, on the ZYN economics, unusually transparent. The CFO went out of his way to pre-explain the $100M one-off and the promotion normalization rather than let the organic-OI deceleration speak for itself, repeating multiple times that the investment is non-repeatable and that U.S. ZYN stays best-in-class on margin. The posture on competition, particularly in Japan, was notably relaxed: management welcomed rivals validating the heat-not-burn category. This was a management team spending confidently into strength, not defending against weakness.

1. The $100M ZYN Relaunch Investment and the Organic OI "Deceleration"

The organic adjusted OI growth of +7.5% (down from +14.9% in Q2) and the trimmed full-year organic OI-growth guide (to 10–11.5% from 11–12.5%) were the numbers the market first reacted to. Both trace to a roughly $100M one-off ZYN cost, effectively all booked as a reduction to Americas net revenue: a special "free can" promotion to mark the brand's return to full availability, plus the cost of restarting a commercial engine that had been throttled during the supply shortage.

"The $100 million is a one-off, non-repeatable. That's all the cost of this special promotion and relaunching the machine. Taking that into account, I'm happy to repeat that we expect ZYN, in this normal situation, to remain very nicely the best-in-class margin in the group." — Emmanuel Babeau, CFO

Assessment: This is the crux of the bull-bear debate on the quarter, and we land firmly on the bull side. A one-off, disclosed reinvestment that drives offtake to +39% in the highest-return market PMI has is a good use of capital, not a margin problem. The market's instinct to sell a headline OI-deceleration is understandable; its intraday recovery suggests it worked out the same math we did.

2. ZYN Offtake +39%: Demand Question Resolved

Covered in Segment Performance, but it carries the rating, so it earns a topic. The +39% Nielsen offtake (30%+ ex-promo, ~30% into early October) directly answers the doubt we raised at initiation: is ZYN's underlying demand as strong as the reported shipments imply? The answer is that offtake is running faster than reported shipments, which is the opposite of the H1 concern. ZYN captured the majority of category growth in both volume and value despite a lower average price during the promo quarter.

Assessment: The demand-quality bear point is retired. What replaces it is a narrower, more manageable question about the normalized promotional intensity and its steady-state margin, which management has framed as still best-in-class. That is a materially better place for the thesis to sit.

3. Record Profitability: 43.1% OI Margin, 67.9% Gross Margin

Adjusted OI margin of 43.1% is the highest in almost four years; gross margin of 67.9% is a record since 2021; smoke-free gross profit crossed $3 billion in a quarter for the first time. The driver is the smoke-free mix at a 70% gross margin, roughly 3.5 points above combustibles, compounding as it takes share. The $2 billion 2024–2026 cost program remains on track.

"We achieved more than $3 billion in quarterly smoke-free gross profit for the first time, and an adjusted group operating income margin of over 43%, the highest in almost four years." — Emmanuel Babeau, CFO

Assessment: The gross-margin engine is the least-appreciated part of the print because the OI-margin optics were muddied by the U.S. reinvestment. Underneath, PMI's unit economics are the best they have been in years, and every point of smoke-free mix shift adds to them mechanically.

4. The 8.9% Dividend Raise

PMI raised its quarterly dividend 8.9% to $1.47 ($5.88 annualized), the 18th consecutive annual increase and the largest since 2013. At the post-print price the yield is ~3.9%. Management framed it as reflecting strong year-to-date performance and confidence in the outlook, alongside continued deleveraging toward the ~2x net-debt/EBITDA target by end-2026.

Assessment: The size of the raise (the largest in twelve years) is a confidence signal that matters. It also improves the total-return math at a de-rated share price: a ~3.9% yield growing high-single-digits, on top of low-teens EPS growth, is a strong base return before any multiple recovery.

5. New Segment Reporting: International SF / International Combustibles / U.S.

Effective January 1, 2026, PMI will replace its four geographic segments with three: International Smoke-Free, International Combustibles, and U.S. Restated 2023–2025 history will be provided after the full-year results. This aligns the organization around the smoke-free transformation and, critically, breaks out the U.S. (i.e., ZYN) as a standalone segment for the first time.

Assessment: Strategically significant and investor-friendly. The single biggest analytical gap in PMI today is the opacity of ZYN's standalone economics, which have been buried inside the Americas geography. A dedicated U.S. segment from 2026 will let the market underwrite ZYN's margin and growth directly, and we expect it to support the valuation as the ZYN profitability that management keeps describing becomes visible in the financials.

6. IQOS in Japan: Competition Intensifies, Share Holds

Two heavily promoted competitor heat-not-burn launches hit Japan during the quarter. IQOS adjusted IMS decelerated to +6.0% (largely the category growth rate), but its ~75%+ share of the heat-not-burn category held, as it has for five to six years. Management welcomed the competitive investment as category-expanding.

Assessment: The bear case on IQOS has always leaned on Japanese competition; Q3 is another data point that the moat holds. A 75%+ category share sustained through repeated well-funded challenges is unusual durability for a consumer-technology category, and it is the foundation of the multi-category cross-sell into ZYN and VEEV.

7. Combustible Pricing Power: +8.3%

Combustible pricing of +8.3% beat expectations, with broad contributions and a post-spin-high 10.9% Marlboro share. Cigarette volume of -3.2% landed at the favorable end of the guide. Management expects Q4 pricing to be somewhat lower on timing/phasing but still positive, with full-year pricing a little above +7%.

Assessment: The combustible model is working as designed: pricing power well ahead of volume decline, generating the gross-profit growth that funds everything else. This is the quiet, reliable half of the story, and it did not wobble.

8. FDA and the ZYN / IQOS ILUMA Regulatory Path

Management flagged the FDA's plan to streamline nicotine-pouch application reviews as a potential positive for a level playing field, noting the FDA has authorized only 20 pouch products to date, all ZYN, with a TPSAC hearing on the ZYN MRTP application expected in 2026. On IQOS ILUMA, the company continues to await U.S. authorization and is running additional IQOS 3 pilots (latest: Jackson, Mississippi) pending a TPSAC-driven MRTP renewal. On the potential ZYN Ultra launch (the 2021 PMTA covering 6mg/9mg and 10 flavors), management declined to speculate on timing but said it is "considering all options."

Assessment: The regulatory picture is incrementally constructive: an FDA move toward streamlining pouch reviews would advantage the incumbent with 20 authorized products. IQOS ILUMA's continued deferral is a mild negative but well-telegraphed, and ZYN is more than carrying the U.S. story in the interim.

9. Capital Allocation and the Q4 Setup

Beyond the dividend raise, management upgraded full-year operating cash flow to more than $11.5 billion (now including a dividend from the deconsolidated Canadian affiliate, RBH) and reiterated the ~2x leverage target for end-2026, with no 2025 buybacks. It also pre-warned that Q4 adjusted OI/EPS growth will look softer (single-digit currency-neutral OI in Q4) on the ZYN and IQOS inventory drawdowns, lower Q4 combustible pricing, continued U.S. investment, and a higher Q4 tax rate (to bring the full year to ~22%).

Assessment: The Q4 softness is entirely mechanical and pre-announced, which de-risks it as a surprise. The capital-allocation posture (deleverage, raise the dividend, reinvest in the U.S., no buybacks yet) is disciplined and appropriate for where PMI is in its balance-sheet repair. Buybacks become a 2026+ lever once leverage hits target.

Guidance & Outlook

The guidance tells a two-part story that is easy to misread. The headline earnings power went up: the EPS-growth floor was raised, cash flow was lifted, and the dividend was increased 8.9%. The organic OI-growth range came down (to 10–11.5%), but for a good reason management stated plainly: higher U.S. investment, including the one-off $100M and a stepped-up commercial program behind ZYN and the IQOS launch preparation. Management noted it could still finish above the old 11% floor depending on Q4, so the trim is conservative rather than a hard reset.

Implied Q4 shape: Management pre-warned a soft Q4 on adjusted OI/EPS: single-digit currency-neutral OI growth, driven by the ~2 billion-unit IQOS shipment reversal, a 20–30 million-can ZYN inventory reduction, lower Q4 combustible pricing on timing, continued U.S. investment, and a higher Q4 tax rate (~20%+ to land the full year near 22%). None of this reflects a change in underlying momentum: management was explicit that consumer offtake and margin drivers are unchanged, and that the Q4 optics are inventory-and-timing mechanics.

Guidance style: Consistent with PMI's pattern of conservative framing. The important tells are the raised EPS floor and the largest dividend increase since 2013, both of which signal genuine confidence, set against a deliberately cautious Q4 optics warning that removes surprise risk.

Analyst Q&A Highlights

ZYN's October Trajectory and the IQOS Shipment-vs-IMS Gap

The opening question probed two things: whether October ZYN scanner data had softened as the September promo eased, and what explained IQOS shipments (+15.5%) running well ahead of IMS (+9%). Management confirmed October offtake was holding near 30% and framed the IQOS gap as a timing benefit set to reverse in Q4.

Q: "With the extraordinary promos of September having eased a bit in October, we've seen the scanner data at least weaken in October, maybe a little surprising in magnitude. How are things tracking in October versus plan? And on IQOS, any additional color on the mismatch between HTU shipments and IMS?"
— Eric Serrano, Morgan Stanley

A: "The first two weeks have been above 30% or a bit below 30% in terms of consumer offtake... if you look at Q3 without the special free-can promotion, we were at 30%-plus growth. So we are starting the last quarter on the same strong note. On IQOS, September was north of 12% HTU shipment growth versus closer to 10% IMS. In Q4 we expect to align shipment and IMS, and I'm not excluding shipment a bit below IMS for the year."
— Emmanuel Babeau, CFO

Assessment: The clean read is that ZYN underlying demand held into October at ~30% and the IQOS shipment gap is a known, self-correcting timing item. The exchange defused the two biggest "is-the-momentum-real" worries the market had going into Q4.

Whether the U.S. Investment Level Is a One-Off or a New Baseline

A recurring line of questioning sought to separate the one-off promotion from the going-forward run-rate of U.S. spending, and to test the claim that ZYN would keep best-in-class margins.

Q: "Thinking about the $100 million of investment in the quarter, is that a sustained level of investment, or a normalized level you face a tough comparison against until this time next year? Or are there other considerations?"
— Matt Smith, Stifel

A: "The $100 million is a one-off, non-repeatable. And the other element is a new level of promotional activity that will be a normal one, significantly higher than the 20% in H1, but not the aggressive level of the rest of the category. Taking that into account, we expect ZYN to remain very nicely the best-in-class margin in the group."
— Emmanuel Babeau, CFO

Assessment: The key distinction: the $100M is gone after Q3, but promotional intensity resets permanently higher (from an abnormally low base) toward a still-premium level. That takes ZYN from an unsustainable H1 margin back to a durable, best-in-class one. It is a step-down in reported margin, not a break in the economics, and it is the right trade for category leadership.

Drivers of the EPS Raise Despite the Lower OI Guide

An analyst pressed the apparent contradiction of a raised EPS guide alongside a lowered organic OI-growth guide, asking what was happening below the line.

Q: "I want to understand the drivers behind your full-year dollar EPS growth guidance raise despite the lower operating income growth guidance. What are the drivers below the line, and how did those factors change since the beginning of the year?"
— Bonnie Herzog, Goldman Sachs

A: "Let's be clear, we continue to expect very strong growth of OI. We are having a slightly better view on the tax rate, and interest costs are evolving in a favorable manner. But fundamentally, the EPS growth, the strong double digit, is coming from the OI growth. That is a powerful engine. Tax is the cherry on the cake."
— Emmanuel Babeau, CFO

Assessment: The reassurance that matters: the EPS raise is not a low-quality tax-and-interest mirage papering over weak operations. The OI engine is intact; below-the-line items are a modest tailwind on top. That framing supports treating the organic-OI trim as investment-driven rather than demand-driven.

The "Free Can" Promotion: New Consumers or Just Discounting?

A question tested whether the September free-can promotion actually recruited new users to the category rather than merely discounting to existing ZYN buyers, and why PMI chose a free-can format over a buy-one-get-one.

Q: "Did the free-can promo actually bring in new consumers to the brand? And why did you choose to run the promo the way you did versus a BOGO?"
— Bonnie Herzog, Goldman Sachs

A: "About 80% of this free-can promotion went to smokers and vapers, and we know future growth will come from converting them. A buy-one-get-one applies to your consumer, you're not recruiting. The objective was to make a big splash, to create the blast, to give people a first connection with this category. As the leader, it is our role to grow the category."
— Emmanuel Babeau, CFO

Assessment: The 80%-to-smokers-and-vapers figure is the important number: the promotion was a customer-acquisition tool aimed at conversion, not a margin giveaway to existing buyers. If repurchase intent converts as management suggests, the one-off cost buys a durable base of new category users, which is exactly the kind of reinvestment that justifies our upgrade.

Japan Competitive Intensity and IQOS's Durability

A question raised the two recent, heavily promoted competitor launches in Japan and asked whether IQOS could maintain its high-single-digit growth given the history of such launches having limited impact.

Q: "You called out intensifying competitive activity, presumably the two product launches in Japan supported by heavy promotion. Historically these have had limited impact on IQOS. Do you think it will be similar this time, and can IQOS maintain its growth in Japan?"
— Faham Baig, UBS

A: "This time it's probably taking even more intensity, which we are happy to see, because it validates that heat-not-burn is a fantastic category for smokers. We remain extremely stable in terms of overall share of this category, north of 75% for the last five, six years, which is quite incredible. Japan is making no exception. We certainly believe we can continue to be a strong leader."
— Emmanuel Babeau, CFO

Assessment: The confident, almost welcoming posture toward competition is credible precisely because the share data backs it: a 75%+ category share sustained for half a decade through repeated challenges. The IMS deceleration to +6% in Japan is category-growth-rate, not share loss, which is the distinction that keeps the IQOS bull case intact.

Visibility on the Q4 Inventory Adjustments

A question probed how much confidence management has in the Q4 inventory drawdowns it flagged for both IQOS and ZYN, given the September promo had already delayed the ZYN reduction.

Q: "What degree of visibility do you have on the inventory adjustment you're expecting in Q4? What's the confidence behind that?"
— Damian McNeil, Deutsche Numis

A: "On IQOS, we expect around 2 billion sticks of adjustment in Q4 as shipment aligns with, and possibly slightly below, IMS. On ZYN, we flagged a higher-than-normal level of wholesaler and distributor inventory, 20 to 30 million cans, that we expect to adjust in the coming months. We expected it in September, but strong promotional activity pushed it out, so I'm a bit more cautious it all lands 100% in Q4."
— Emmanuel Babeau, CFO

Assessment: The candor about timing uncertainty (the ZYN drawdown slipping from Q3) is a modest negative for Q4 predictability, but it is inventory noise, not demand. The important point is that both adjustments are pipeline-normalization mechanics on top of accelerating offtake, which is precisely the benign kind of shipment volatility.

What They're NOT Saying

1. A quantified steady-state ZYN margin. Management insists U.S. ZYN stays "best-in-class in the group," but with promotional intensity resetting permanently higher and the segment buried inside Americas, there is no number to anchor to. The January 2026 U.S. segment disclosure is what will finally force this into the open.
2. 2026 guidance, beyond a similar ~10-cent currency tailwind. Management declined to guide 2026 despite repeated openings, and specifically would not say whether the elevated U.S. investment continues at the same pace, other than that it "will continue in the future."
3. The magnitude of the September promo's new-user conversion. Management said ~80% of the free-can promo reached smokers and vapers with "promising" repurchase intent, but explicitly could not yet quantify how many became repeat ZYN buyers, the number that determines the promo's actual ROI.
4. A firm IQOS ILUMA U.S. timeline. Again deferred; management "won't speculate" on FDA timing and would not commit to launching ahead of authorization the way some peers are.
5. Whether the organic OI trim is fully one-off. Management framed the guide cut as US-investment-driven and hinted it could still exceed the old 11% floor, but stopped short of confirming organic OI growth re-accelerates back above 11.5% in 2026.

Market Reaction

• Pre-print setup (Oct 20 close): $158.06, up ~31.3% year-to-date but down ~3.0% over the trailing 30 days. The stock had already de-rated materially from the ~$180 level it carried into the July print, so it entered Q3 far less crowded than it was in the summer.
• Reaction session (Oct 21): Gapped down ~2% at the open, sold off to as low as $142.33 intraday (down ~10%) on the organic-OI-guide optics, then recovered through the session to close at $152.00, down 3.8% (-$6.06).
• Volume: 28.4M shares versus a 6.0M 30-day average (4.7x), consistent with a high-conviction repricing debate that resolved toward the middle.
• Market context: The S&P 500 was flat (0.0%) on the session; the move was entirely idiosyncratic to PMI.

The intraday round-trip is the most informative feature of the reaction. The initial 10% drop was a reflexive sell of the headline organic-OI deceleration and the trimmed guide. The recovery to -3.8% came as the market digested three things: the deceleration is a deliberate one-off ZYN investment, the underlying demand signal (offtake +39%) actually accelerated, and the company raised both the EPS floor and the dividend. That is a tape working out that the quarter was better than its first-glance optics.

For our purposes, the reaction is doubly constructive. It confirms the de-rating (the stock is now ~20x forward, well below the ~24x it carried in early summer), and the intraday recovery signals that the incremental marginal buyer is already looking through the U.S.-investment noise. We are upgrading into a stock that the market itself has started to re-underwrite on the merits.

Street Perspective

Debate: Is the Organic OI Trim a Warning or a Reinvestment?

Bull view: The organic-OI-guide cut is 100% a deliberate, disclosed, one-off-plus-normalized U.S. investment that is driving +39% ZYN offtake in the highest-return market PMI has. Spending into a category leadership position that can eventually rival cigarettes in size is the best possible use of the gross-margin windfall. The EPS floor went up and the dividend rose 8.9%, which is not what a company in trouble does.

Bear view: A guide cut is a guide cut. Promotional intensity that resets permanently higher structurally lowers ZYN's margin, competition is validating that pouches are becoming a price-competitive category, and management would not quantify the steady-state margin. The abnormally-high H1 U.S. profitability that flattered the first half is now unwinding, and the "one-off" may prove stickier than claimed.

Our take: Strongly bull. The distinction between the $100M one-off and the permanent-but-still-premium promotion level is real and management was unusually transparent about both. A reinvestment that accelerates offtake to +39% while the gross-margin engine runs at a record is a margin-mix trade we want, not a margin break we should fear. Margin quality becomes the watch item, but the burden of proof has shifted to the bears.

Debate: Has ZYN's Underlying Demand Actually Accelerated, or Was It a Promo Sugar-High?

Bull view: Ex-promo offtake was 30%+ in Q3 and held near 30% into early October, so the +39% headline was not a one-time sugar-high; the underlying trend is genuinely faster than the reported shipments. ZYN captured the majority of category growth in both volume and value, and the category itself is compounding above 40%. Capacity is unconstrained.

Bear view: The +39% was flattered by a September blast that spiked to +58%; October scanner data softened; and a 20–30 million-can inventory drawdown is still coming. The "true" run-rate could settle back toward the high-20s as the promo comps get harder, and international pouch expansion is still small.

Our take: Bull. The ex-promo 30%+ figure is the number that matters, and it is excellent. We would not underwrite a sustained +39%, but a durable high-20s-to-30% offtake growth in a 40%-growth category, from the clear leader, is more than enough to validate the second U.S. growth leg that anchors the ZYN part of our thesis.

Debate: Is IQOS's Deceleration to +9% IMS a Problem?

Bull view: The +9% IMS is against a ~15% prior-year comp, September was already back above 10%, and management reaffirmed 10–12% full-year IMS with a Q4 acceleration. Japan share held at ~75%+ through two heavily promoted competitor launches. This is a comp-and-timing dip in a franchise that is structurally intact.

Bear view: Two straight quarters of IMS deceleration (from +11.4% to +9%) plus intensifying Japanese competition could mark the beginning of maturation in IQOS's core markets, with the newer growth markets not yet large enough to offset a slowing Japan and Europe.

Our take: Bull, with IQOS IMS as the one metric we are watching most closely. The comp explanation is credible and the share stability is compelling, but a third consecutive quarter of deceleration in Q4 (against the promised acceleration) would be a genuine yellow flag. For now, the evidence supports the durable-compounder view.

Debate: Valuation After the De-Rating

Bull view: At $152, ~20x forward with a ~3.9% yield and low-teens EPS growth, PMI has de-rated ~8% since July even as the smoke-free franchise accelerated. The new U.S. segment disclosure in 2026 is a catalyst to surface ZYN's economics. The total-return algorithm (low-teens EPS growth plus ~3.9% yield growing high-single-digits) beats the market comfortably if the multiple merely holds.

Bear view: Twenty times is still a premium tobacco multiple, the market has repeatedly shown it will punish any smoke-free wobble, and the ESG buyer constraint caps the multiple regardless of mix. The stock could stay range-bound until the U.S. segment economics are proven in 2026.

Our take: Bull. The de-rating to ~20x is the improved entry we said we were waiting for at initiation, and it now sits against an accelerating demand signal and a raised dividend. The asymmetry has flipped from balanced (at $165 in July) to favorable (at $152 today).

Model & Valuation Framework

Valuation: At $152 and an FY25 adjusted EPS midpoint of ~$7.51, PMI trades at ~20.2x forward earnings with a ~3.9% dividend yield, versus ~22x at our July initiation. The stock has de-rated roughly two turns even as the smoke-free franchise accelerated and the dividend grew 8.9%. On a forward FY26 EPS of ~$8.60, PMI trades at ~17.7x, a level at which a low-teens-EPS-growth compounder with a ~3.9% growing yield offers a compelling total-return algorithm.

12-month price target framework: Base case ~$180–190 (roughly 23–24x our ~$8.10 blended NTM EPS, modest multiple recovery toward the July level as the U.S. segment disclosure surfaces ZYN's economics), implying ~18–25% upside plus the ~3.9% yield. Bull case ~$205–215 (25x on $8.60 if ZYN offtake holds near 30%+, IQOS IMS re-accelerates to double digits, and the market re-rates toward a staples-platform premium). Bear case ~$135–145 (17x on $8.00 if the ZYN margin reset proves deeper than "one-off," IQOS maturation accelerates, or a regulatory/FX shock hits). The up-to-down skew from $152 is now clearly favorable (~+25% bull / ~-8% bear), which supports the upgrade to Outperform.

Thesis Scorecard Post-Earnings

We grade the standing thesis established at our July initiation. The headline development is that the bear point which anchored our Hold (ZYN demand-quality) has resolved favorably, and the valuation bear point has eased on the de-rating, clearing the path to the upgrade.

Overall: Thesis strengthened. Three of four bull pillars confirmed or strengthened; the fourth (IQOS) is a comp-driven neutral we are watching. The two bear points that mattered most in July (valuation and ZYN demand-quality) have eased and resolved, respectively. A new, narrower bear point (ZYN margin quality) replaces the old broad one, which is a better trade for the thesis.

Action: Upgrade to Outperform from Hold. The two upgrade conditions set at initiation are both met: the stock de-rated to ~20x (improved entry) and ZYN offtake accelerated to +39% (demand confirmed). We would move back to Hold if the ZYN margin reset proves structurally deeper than management's "one-off plus normalized" framing, or if IQOS IMS decelerates for a third straight quarter against the promised Q4 acceleration. We would consider Underperform only on evidence of an outright pricing rollover or a demand break, neither of which is remotely in the data.

Bottom Line: The Proof and the Price Line Up

Three months ago we initiated at Hold because a best-in-class transformation was trading at a price that demanded perfection, with one open question, ZYN's underlying demand, hanging over the growth premium. Q3 closed that question emphatically: offtake accelerated to +39% (30%+ underlying), ZYN captured the majority of a 40%-growing category, and management put real one-off money behind acquiring the next cohort of category users. At the same time, the stock has de-rated roughly two turns to ~20x, exactly the improved entry we said would move us off the sidelines.

The market's initial instinct was to sell the organic-OI optics, and the intraday round-trip from -10% to -3.8% shows it thought better of it within hours. We think it was right to. A one-off, disclosed reinvestment that drives the fastest offtake growth in five quarters, layered on record gross margins and a four-year-high OI margin, is the sign of a company pressing an advantage, not defending a weakness. The 8.9% dividend raise, the largest since 2013, is the exclamation point.

We are upgrading to Outperform. The IQOS IMS deceleration keeps our conviction at moderate rather than high, and ZYN margin quality is the new number we will track quarter by quarter. But at ~20x with a ~3.9% growing yield, an accelerating smoke-free franchise, and a 2026 catalyst in the standalone U.S. segment disclosure, the risk/reward has flipped from balanced to favorable. This is the setup we were waiting for.